Clinical Trial Update: Efficacy of Ketorolac 0.4% in Prostaglandin Suppression [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy of ketorolac 0.4% in suppressing prostaglandin activity. Results were completed and posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammation

Drugs mentioned

• Ketorolac 0.4% ophthalmic solution (ketorolac tromethamine)

Snippet

Sponsor: Allergan | Conditions: Inflammation | Phase 4 | Status: COMPLETED | Results posted: 2011-09-23